Literature DB >> 34050808

Expression of thrombospondin-1 in conjunctival squamous cell carcinoma is correlated to the Ki67 index and associated with progression-free survival.

Mizuki Tagami1,2, Anna Kakehashi3, Atsushi Sakai4, Norihiko Misawa4, Atsuko Katsuyama-Yoshikawa5, Hideki Wanibuchi3, Atsushi Azumi5, Shigeru Honda4.   

Abstract

PURPOSE: Conjunctival squamous cell carcinoma (SCC) is primarily treated with surgical resection. SCC has various stages, and local recurrence is common. The purpose of this study was to investigate thrombospondin-1 expression and its association with prognosis.
METHODS: In this retrospective study, a gene expression array along with immunohistochemistry were performed for the evaluation of thrombospondin-1 expression, localization, as well as Ki67 labeling cell indices in carcinoma in situ (Tis) and advanced conjunctival SCC (Tadv). The presence or absence and intensity of cytoplasmic and nuclear staining in tumor cells were also divided into groups with a score of 0-3 and semi-quantitatively analyzed to investigate intracellular staining patterns. The association between thrombospondin-1 expression and tumor progression in a series of 31 conjunctival SCCs was further investigated.
RESULTS: All 31 patients in the cohort (100%) were East Asian. A simple comparison between Tis and Tadv demonstrated significant differences in expressions of 45 genes, including thrombospondin-1 (p < 0.01). In this cohort, 30/31 tumors were positive (96%) for thrombospondin-1. Furthermore, thrombospondin-1 intracellular staining pattern analysis scores were 2.12 and 0.96 for nuclear and cytoplasmic staining, respectively, with a significant difference observed between Tis and Tadv (p < 0.01). Alteration of the Ki67 labeling index was significantly correlated with that of the thrombospondin-1 cytoplasmic score (p = 0.030). Furthermore, univariate Cox regression analysis showed a significant correlation between thrombospondin-1 staining and progression-free survival (p = 0.026) and final orbital exenteration (p = 0.019).
CONCLUSIONS: The present results demonstrated that thrombospondin-1 is a potential molecular target in the pathology of conjunctival SCC, in addition to serving as a prognostic factor.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Asian population; Conjunctival squamous cell carcinoma; Immunohistochemistry; Ki67 index; Thrombospondin-1

Mesh:

Substances:

Year:  2021        PMID: 34050808     DOI: 10.1007/s00417-021-05236-7

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  25 in total

1.  Polymorphism in THBS1 gene is associated with post-refractive surgery chronic ocular surface inflammation.

Authors:  Laura Contreras-Ruiz; Denise S Ryan; Rose K Sia; Kraig S Bower; Darlene A Dartt; Sharmila Masli
Journal:  Ophthalmology       Date:  2014-03-27       Impact factor: 12.079

2.  Unique distribution of thrombospondin-1 in human ocular surface epithelium.

Authors:  Eiichi Sekiyama; Takahiro Nakamura; Leanne J Cooper; Satoshi Kawasaki; Junji Hamuro; Nigel J Fullwood; Shigeru Kinoshita
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-04       Impact factor: 4.799

Review 3.  Ocular surface squamous neoplasia.

Authors:  G A Lee; L W Hirst
Journal:  Surv Ophthalmol       Date:  1995 May-Jun       Impact factor: 6.048

4.  Conjunctival squamous cell carcinoma: prognostic factors for the recurrence and metastasis and clinicopathological characteristics at an oncological hospital in Peru.

Authors:  Deivy Cruzado-Sanchez; Walter Andree Tellez; Beltran Villarreal-Aguilar; Monica Melendez; Anibal Olivera; Fiorella Moran; Solon Serpas-Frias; Raul Cordero-Garcia
Journal:  Br J Ophthalmol       Date:  2019-10-11       Impact factor: 4.638

5.  Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas.

Authors:  M Streit; P Velasco; L F Brown; M Skobe; L Richard; L Riccardi; J Lawler; M Detmar
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

6.  B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression.

Authors:  Carmelo Nucera; Alessandro Porrello; Zeus Andrea Antonello; Michal Mekel; Matthew A Nehs; Thomas J Giordano; Damien Gerald; Laura E Benjamin; Carmen Priolo; Efisio Puxeddu; Stephen Finn; Barbara Jarzab; Richard A Hodin; Alfredo Pontecorvi; Vânia Nose; Jack Lawler; Sareh Parangi
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-24       Impact factor: 11.205

7.  Frequent TERT Promoter Mutations in Ocular Surface Squamous Neoplasia.

Authors:  Simone L Scholz; Henning Thomasen; Henning Reis; Inga Möller; Raid Darawsha; Bettina Müller; Dirk Dekowski; Antje Sucker; Bastian Schilling; Dirk Schadendorf; Klaus-Peter Steuhl; Annette Paschen; Henrike Westekemper; Daniel Meller; Klaus G Griewank
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-09       Impact factor: 4.799

8.  Deciphering the complex role of thrombospondin-1 in glioblastoma development.

Authors:  Thomas Daubon; Céline Léon; Kim Clarke; Laetitia Andrique; Laura Salabert; Elodie Darbo; Raphael Pineau; Sylvaine Guérit; Marlène Maitre; Stéphane Dedieu; Albin Jeanne; Sabine Bailly; Jean-Jacques Feige; Hrvoje Miletic; Marco Rossi; Lorenzo Bello; Francesco Falciani; Rolf Bjerkvig; Andréas Bikfalvi
Journal:  Nat Commun       Date:  2019-03-08       Impact factor: 14.919

9.  PD-L1/PD1 Expression, Composition of Tumor-Associated Immune Infiltrate, and HPV Status in Conjunctival Squamous Cell Carcinoma.

Authors:  Priyadharsini Nagarajan; Christian El-Hadad; Stephen K Gruschkus; Jing Ning; Courtney W Hudgens; Oded Sagiv; Neil Gross; Michael T Tetzlaff; Bita Esmaeli
Journal:  Invest Ophthalmol Vis Sci       Date:  2019-05-01       Impact factor: 4.799

View more
  1 in total

1.  FOXP3 and CXCR4-positive regulatory T cells in the tumor stroma as indicators of tumor immunity in the conjunctival squamous cell carcinoma microenvironment.

Authors:  Mizuki Tagami; Anna Kakehashi; Atsuko Katsuyama-Yoshikawa; Norihiko Misawa; Atsushi Sakai; Hideki Wanibuchi; Atsushi Azumi; Shigeru Honda
Journal:  PLoS One       Date:  2022-03-31       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.